Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression. By integrating genomic, transcriptomic and proteomic data, the platform accelerates target identification and reduces the timelines typically associated with early-stage drug discovery. The company applies this technology both to its internally developed pipeline and to partnered research programs.
The company’s pipeline includes multiple clinical-stage immuno-oncology candidates, among them checkpoint modulators advancing in Phase 1 trials for solid tumors. In parallel, Compugen is developing companion diagnostic and biomarker assays designed to predict patient response and optimize therapeutic regimens. Strategic collaborations with global pharmaceutical partners have enabled the advancement of select programs into later-stage development and expanded the geographic reach of its assets.
Over its three-decade history, Compugen has built a multidisciplinary team of computational biologists, immunologists and clinical development experts. This leadership group oversees both discovery and translational research efforts, with the goal of delivering novel immunotherapy solutions across North America, Europe and Asia. Through its integrated approach, Compugen aims to bring first-in-class therapies and precision diagnostic tools to patients with unmet medical needs.
AI Generated. May Contain Errors.
Free CGEN Stock Alerts